Baidu
map

J Hepatol:针对性疫苗接种计划降低男男性行为者急性乙型肝炎发生率

2013-09-03 佚名 丁香园

2011年间阿姆斯特丹男男性行为者急性乙型肝炎发生率 在荷兰,乙型肝炎病毒主要在高危行为人群之间传播,比如男男性行为者。因此,研究者特定为这类高危人群制定了针对性疫苗接种计划。在此基础上,来自荷兰阿姆斯特丹传染病科的Gini van Rijckevorsel等人展开一项研究,旨在评估1998年-2011年间针对阿姆斯特丹大量男男性行为者的疫苗接种计划的影响。他们的研究结果在线发表于2013年


2011年间阿姆斯特丹男男性行为者急性乙型肝炎发生率

在荷兰,乙型肝炎病毒主要在高危行为人群之间传播,比如男男性行为者。因此,研究者特定为这类高危人群制定了针对性疫苗接种计划。在此基础上,来自荷兰阿姆斯特丹传染病科的Gini van Rijckevorsel等人展开一项研究,旨在评估1998年-2011年间针对阿姆斯特丹大量男男性行为者的疫苗接种计划的影响。他们的研究结果在线发表于2013年8月14日的《肝脏病学杂志》(Journal of Hepatology)上。作者发现,尽管高危性行为仍持续存在,但该疫苗接种计划有效降低了阿姆斯特丹男男性行为者之间乙型肝炎病毒的传播率。

研究人员采用了来自高危人群疫苗接种计划国家数据库中阿姆斯特丹的资料,时间范围为1998年1月1日至2011年12月31日。根据人口统计结果估计疫苗接种计划和疫苗接种的覆盖范围。利用来自阿姆斯特丹公共卫生服务部在1992年至2011年间的通报数据分析急性乙型肝炎的发生率。并利用相应的数学模型来研究疫苗接种计划的影响,这些数学模型可解释危险性行为人群疫苗接种的数据和趋势。

研究结果如下:至2011年底,疫苗接种计划的估计覆盖率为41%,而疫苗覆盖率为30%-38%.该研究所招募的大多数参试者来自性传播感染门诊部和桑拿和同性恋酒吧等地点。在2005年之后,急性乙型肝炎发生率急剧下降。其中的一个数学模型能够最好地解释发病率的下降,在该模型中,那些最常发生高危性行为者接种了疫苗。

研究发现,在阿姆斯特丹,尽管高危性行为仍持续存在,但男男性行为者之间乙型肝炎病毒的传播已经有所降低。针对男男性行为者的疫苗接种计划并不需要实现百分之百的覆盖率,只要那些最经常进行高危性行为的人群接种了疫苗,该计划或许就能够奏效了。

原文下载

Rijckevorsel GV, Whelan J, Kretzschmar M, Siedenburg E, Sonder G, Geskus R, Coutinho R, Hoek AV. Targeted vaccination programme successful in reducing acute Hepatitis B in men having sex with men in Amsterdam, The Netherlands. J Hepatol. 2013 Aug 13. pii: S0168-8278(13)00555-2. doi: 10.1016/j.jhep.2013.08.002.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825584, encodeId=1ba21825584e5, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Thu Jun 19 02:28:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826233, encodeId=9a68182623306, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 19 14:28:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257806, encodeId=d6a0125e80677, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322343, encodeId=9ab01322343d2, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378897, encodeId=73e313e889785, content=<a href='/topic/show?id=7dafe027380' target=_blank style='color:#2F92EE;'>#男男性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70273, encryptionId=7dafe027380, topicName=男男性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426548, encodeId=ad1e142654887, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1825584, encodeId=1ba21825584e5, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Thu Jun 19 02:28:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826233, encodeId=9a68182623306, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 19 14:28:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257806, encodeId=d6a0125e80677, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322343, encodeId=9ab01322343d2, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378897, encodeId=73e313e889785, content=<a href='/topic/show?id=7dafe027380' target=_blank style='color:#2F92EE;'>#男男性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70273, encryptionId=7dafe027380, topicName=男男性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426548, encodeId=ad1e142654887, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1825584, encodeId=1ba21825584e5, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Thu Jun 19 02:28:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826233, encodeId=9a68182623306, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 19 14:28:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257806, encodeId=d6a0125e80677, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322343, encodeId=9ab01322343d2, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378897, encodeId=73e313e889785, content=<a href='/topic/show?id=7dafe027380' target=_blank style='color:#2F92EE;'>#男男性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70273, encryptionId=7dafe027380, topicName=男男性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426548, encodeId=ad1e142654887, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1825584, encodeId=1ba21825584e5, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Thu Jun 19 02:28:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826233, encodeId=9a68182623306, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 19 14:28:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257806, encodeId=d6a0125e80677, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322343, encodeId=9ab01322343d2, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378897, encodeId=73e313e889785, content=<a href='/topic/show?id=7dafe027380' target=_blank style='color:#2F92EE;'>#男男性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70273, encryptionId=7dafe027380, topicName=男男性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426548, encodeId=ad1e142654887, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
    2013-09-05 xugc
  5. [GetPortalCommentsPageByObjectIdResponse(id=1825584, encodeId=1ba21825584e5, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Thu Jun 19 02:28:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826233, encodeId=9a68182623306, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 19 14:28:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257806, encodeId=d6a0125e80677, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322343, encodeId=9ab01322343d2, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378897, encodeId=73e313e889785, content=<a href='/topic/show?id=7dafe027380' target=_blank style='color:#2F92EE;'>#男男性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70273, encryptionId=7dafe027380, topicName=男男性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426548, encodeId=ad1e142654887, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1825584, encodeId=1ba21825584e5, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Thu Jun 19 02:28:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826233, encodeId=9a68182623306, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 19 14:28:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257806, encodeId=d6a0125e80677, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322343, encodeId=9ab01322343d2, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378897, encodeId=73e313e889785, content=<a href='/topic/show?id=7dafe027380' target=_blank style='color:#2F92EE;'>#男男性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70273, encryptionId=7dafe027380, topicName=男男性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426548, encodeId=ad1e142654887, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 05 04:28:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
    2013-09-05 gwc384

相关资讯

乙肝合并丙肝病毒感染伴2型糖尿病1例

  一、病例资料   患者男性,63岁。广东湛江人,汉族,退休教师。因反复疲乏、纳差、尿黄15年余于2009年4月27日就诊。患者15年前无明显诱因出现疲乏,食欲不振,身目黄染、尿黄,曾到广东省人民医院就诊,检查发现肝功能异常,丙型肝炎抗体为阳性,诊断为“急性丙型肝炎”,给予护肝治疗1月余,症状缓解。   14年前曾用普通干扰素治疗1月余,因出现严重的骨髓抑制自行停药

Gastroenterology:黑猩猩试验表明TLR-7口服激动剂GS-9620或可治疗慢性乙型肝炎

对于慢性乙型肝炎的治疗来说,直接抗病毒药物能够抑制乙型肝炎病毒(HBV)载量,但需终生服用。相比之下,刺激先天免疫系统能提高机体对病毒的控制能力,而且在有限的治疗之后获得长期效应。因此,来自美国德克萨斯州圣安东尼奥市德州生物医学研究所病毒学与免疫学部门的ROBERT E. LANFORD等人展开一项研究,研究结果于2013年2月14日在线发表于《胃肠病学》(Gastroenterology)杂志上

庄辉:抗乙型肝炎病毒新药研究进展

   6月21-22日,第十六次全国病毒性肝炎及肝病学术会议在云南昆明召开。来自32个省市及自治区的1625名学者参加了此次年会。今年会议专题报告为35个,其中15个与“十一五”、“十二五”国家科技重大专项有关,内容包括肝衰竭及终末期肝病、非传染性肝病、慢性乙型肝炎、丙型肝炎4方面。  “在本届会议,李兰娟院士、庄辉院士、贾继东教授等5位学者的大会主题发言各具特色、值得关注;另外,大会首

Cell Stem Cell:肝干细胞获得或有新“种源”

  第二军医大学基础部细胞生物学教研室主任胡以平教授课题组,通过4年攻关,实现了小鼠成纤维细胞向肝干细胞分化的重编程, 并证明通过这种重编程方法所产生的肝干细胞,具有与活体内自然存在的肝干细胞相似的生物学特性。相关研究成果7月18日发表于《细胞·干细胞》(Cell Stem Cell)杂志。 肝干细胞是肝脏中数量极少、但可分化产生肝细胞和胆管上皮细胞的种

肝损害及乙型肝炎再活动1例

  病历摘要   现病史 患者女性,57岁,因胃脘不适3个月、乏力1个月于2011年8月11日就诊。患者20余年前感染乙型肝炎病毒(HBV),定期到我院随访。近10年来多次随访,肝功能均正常,HBV DNA< 500拷贝/毫升,HBsAg(+),HBeAg(-),HBeAb(+)。诊断为非活动性HBsAg携带者。   2011年3月患者在家不慎滑倒致

AJG:口服抗病毒药物可有效预防肝移植后乙型肝炎的复发

乙肝患者行肝移植术后联用抗病毒药物及B型肝炎免疫球蛋白能有效降低移植术后肝炎的复发。但单用抗病毒药物进行治疗的预防作用和长期预后方面仍缺乏相应研究。香港大学玛丽女王医院的James Fung等人利用大样本量的肝移植术后乙肝患者单独口服抗病毒药物的实验方法,评估该方法对此类患者长期预后的影响。作者发现,单独应用核苷/核苷酸类似物抗病毒治疗能够有效预防因肝移植术后乙肝复发而引起的移植物坏死。该结果发表

Baidu
map
Baidu
map
Baidu
map